Abbott Laboratories lifted to buy at Goldman Sachs. 0 Comments. Tweet. new. Portfolio Relevance. LEARN MORE. Want to see how this story relates to your portfolio?

In a report published Sunday, Goldman Sachs analyst David H. Roman upgraded the rating on Abbott Laboratories (NYSE: ABT) from Neutral to Buy and raised the price target on the company from $38.00 to $44.00.

How does Abbott Laboratories stock fare against its peers in health care? Let's use the SPDR Health Care Select ETF (NYSEMKT: XLV ) as a proxy to represent the health-care industry as a whole.

Investors in Abbott Laboratories Abbott Laboratories (NYSE: ABT) saw new options begin trading today, for the July expiration.

The jury entered a verdict in favor of plaintiff Milton Tietz on behalf of his wife, Delores Tietz and found Abbott Park-based Abbott Labs (NYSE: ABT) negligent for not taking reasonable measures to alert doctors about the side-effect risk of ...

Abbott continues to offer physicians more options for the treatment of patients with complex coronary artery disease and is the only major manufacturer to offer a coronary drug eluting stent greater than 38 mm in length.

Abbott Laboratories stock hit a high in October of last year of 72.47, but when the new year hit, the company split in two, spinning its drug assets into AbbVie (NYSE: ABBV ) .

Cornucopia, WI -- Shareholders of Abbott Laboratories will vote on whether the manufacturer of Similac, a leading brand of infant formula, should adopt a policy of sourcing ingredients that have not been genetically engineered.

After spinning off its pharmaceutical business -- and most of its dividend, essentially -- you may think Abbott Laboratories (NYSE: ABT ) is relegated to a boring medical-device company. Heart stents just aren't as sexy as the megablockbuster drugs now ...

Prior to the spinoff of Abbvie (ABBV) from Abbott Labs (ABT) in early 2013 the joint company used to pay a pretty good dividend of 2.83% and post-split Abbott now pays a 1.52% yield while Abbvie pays a 3.58% yield.